Tuesday, September 8, 2026
Medvi and Elixamd are the only rising AI tools sustaining absolute traction at 100, while generalist agents like Runable AI and Embody AI crashed over 90% within two weeks. Meanwhile, Claude's landmark Fermat proof barely moved search interest, signaling that consumer attention has decoupled from research breakthroughs.
Ongoing Stories(5)
Medvi
Still TrendingMedvi search interest reached 100 on Sep 8, sustaining its 18x climb from June.
See previous coverageElixamd
Major UpdateElixamd search interest surged to 100 by Sep 8, matching Medvi's peak and confirming vertical telehealth demand.
See previous coverageGoogle Flow
Still TrendingGoogle Flow remains stable at 10-12 search interest, outlasting feature-level hype cycles.
See previous coverageOpenClaw
Still TrendingOpenClaw holds steady at 17-21, the last surviving AI agent framework with sustained search interest.
See previous coverageHermes AI Agent
Winding DownHermes AI interest flatlined at 3-5, confirming the collapse of generalist AI agent frameworks.
See previous coverageVisualizations(4)
Rising Tool Reality Check: Peak vs Current Interest
Medvi and Elixamd sustained peak interest at 100, while Runable AI crashed from 33 to 2 and Embody AI fell from 66 to 5.
Medvi Hits 100 as Runable AI Fades
Medvi surged to 100 by Sep 8 while Google Flow held steady at 10-12; Runable AI dropped from a 33 peak to 2 and Dola AI flatlined at 1.
Developer AI Tools: Embody Crashes, OpenClaw Holds
Embody AI collapsed from 66 to 5 after a late-August spike, while OpenClaw maintained 17-21 and Hermes flatlined at 3-5.
Claude Interest Muted Despite Fermat Proof Milestone
Claude AI search interest rose only 37% from 24 to 33 after proving Fermat's Last Theorem, while Gemini AI maintained higher baseline interest at 38-49.